Roche’s EU Accelerated Assessment Bid For Tumor Agnostic Entrectinib Backfires

 
• By Alexandra Shimmings

A decision to yoke together two indications in one EU accelerated assessment filing for the anticancer has backfired on Roche and left the product at even more of a disadvantage compared with Bayer’s Vitrakvi in the tumor-agnostic setting.

Oxen
Unequally yoked: one indication holds back the other

More from Business

More from Scrip